Chimerix Drug Patent Portfolio
Chimerix owns 1 orange book drug protected by 7 US patents Given below is the list of Chimerix's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10172862 | Imipridones For Gliomas | 30 Jan, 2037 | Active |
| US10369154 | Imipridones For Gliomas | 30 Jan, 2037 | Active |
| US12102639 | Imipridones For Gliomas | 30 Jan, 2037 | Active |
| US11976068 | 7-Benzyl-4-(2-Methylbenzyl)-2,4,6,7,8,9-Hexahydroimidazo [1,2-A]Pyrido[3,4-E]Pyrimidin-5(1H)-One, Analogs Thereof, And Salts Thereof And Methods For Their Use In Therapy | 01 Mar, 2036 | Active |
| US9265765 | 7-Benzyl-10-(2-Methylbenzyl)-2,6,7,8,9,10-Hexahydroimidazo[1,2-A]Pyrido[4,3-D]Pyrimidin-5(3H)-One, Salts Thereof And Methods Of Using The Same In Combination Therapy | 26 Jul, 2034 | Active |
| US9629842 | Small Molecule Trail Gene Induction By Normal And Tumor Cells As An Anticancer Therapy | 30 Apr, 2032 | Active |
| USRE46290 | 30 Apr, 2032 | Active |
Latest Legal Activities on Chimerix's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Chimerix.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 11 Jul, 2025 | US10172862 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 11 Jul, 2025 | US9265765 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 11 Jul, 2025 | USRE46290 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 11 Jul, 2025 | US11976068 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 11 Jul, 2025 | US10369154 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 11 Jul, 2025 | US9629842 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 11 Jul, 2025 | US12102639 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 25 Oct, 2024 | US9629842 |
| Email Notification | 01 Oct, 2024 | US12102639 |
| Mail Patent eGrant Notification | 01 Oct, 2024 | US12102639 |
| Patent Issue Date Used in PTA Calculation | 01 Oct, 2024 | US12102639 |
| Recordation of Patent eGrant | 01 Oct, 2024 | US12102639 |
| Patent eGrant Notification | 01 Oct, 2024 | US12102639 |
| Recordation of Patent Grant Mailed | 01 Oct, 2024 | US12102639 |
| Email Notification | 12 Sep, 2024 | US12102639 |
Chimerix's Family Patents
Chimerix Drug List
Given below is the complete list of Chimerix's drugs and the patents protecting them.
1. Modeyso
Modeyso is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10172862 | Imipridones For Gliomas |
30 Jan, 2037
(10 years from now)
| Active |
| US10369154 | Imipridones For Gliomas |
30 Jan, 2037
(10 years from now)
| Active |
| US12102639 | Imipridones For Gliomas |
30 Jan, 2037
(10 years from now)
| Active |
| US11976068 | 7-Benzyl-4-(2-Methylbenzyl)-2,4,6,7,8,9-Hexahydroimidazo [1,2-A]Pyrido[3,4-E]Pyrimidin-5(1H)-One, Analogs Thereof, And Salts Thereof And Methods For Their Use In Therapy |
01 Mar, 2036
(9 years from now)
| Active |
| US9265765 | 7-Benzyl-10-(2-Methylbenzyl)-2,6,7,8,9,10-Hexahydroimidazo[1,2-A]Pyrido[4,3-D]Pyrimidin-5(3H)-One, Salts Thereof And Methods Of Using The Same In Combination Therapy |
26 Jul, 2034
(8 years from now)
| Active |
| US9629842 | Small Molecule Trail Gene Induction By Normal And Tumor Cells As An Anticancer Therapy |
30 Apr, 2032
(6 years from now)
| Active |
| USRE46290 |
30 Apr, 2032
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Modeyso's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List